MT Group Signs Contract with Ørsted to Build Large-scale CO2 Capture and Storage Facility in Denmark
MT Group, an EPC contractor engaged in strategic energy and industrial infrastructure projects across Europe, has signed a contract with Danish energy leader Ørsted for the engineering and construction of Balance of Plant (BoP) piping and equipment for a carbon capture facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240915027054/en/
Mindaugas Zakaras, CEO of MT Group (Photo: Business Wire)
"The signing of this contract is a significant milestone for MT Group and a strong testament to our commitment to driving the renewable energy transition across Europe," says Mindaugas Zakaras, CEO of MT Group.
Advancing Global Efforts to Combat Climate Change
This contract is part of Ørsted's 20-year agreement with the Danish Energy Agency (DEA) for the ambitious carbon capture and storage (CCS) project, the ‘Ørsted Kalundborg CO2 Hub.’ It aims to capture and store 430,000 tons of CO2 annually from two Ørsted Power stations. The captured CO2 will be transported to Northern Lights in Norway for geological storage, contributing to global efforts to combat climate change.
Under this agreement, MT Group will handle the engineering and construction of piping for the BoP equipment for the CO2 capture and storage facility including installation of BoP equipment. Responsibilities include finalizing the BoP facility's design and integrating it with the existing woodchip-fired boiler plant and the new CO2 capture and storage facility at Asnæsværket, Denmark.
MT Group will also oversee the procurement, supply, construction, and installation of the entire cooling and steam systems, including pipelines, to the interface of the CO2 capture and storage units. Additionally, the company will ensure the scope of supply undergoes rigorous testing and commissioning to meet all regulatory and operational standards before it becomes fully operational.
Strengthening MT Group's Renewable Energy Portfolio
This contract aligns with MT Group’s strategic focus on the renewable energy transition. “We have firmly established MT Group as a strong and reliable EPC contractor, particularly in the development of complex natural gas and LNG projects across Europe. This contract marks a significant step in our expansion in the green energy markets and strengthens our position in this rapidly growing area,” adds Mindaugas Zakaras.
MT Group is a leading EPC contractor in critical energy and industrial infrastructure projects across Europe. The company is also a founding partner in one of the largest Renewable Energy undertakings in the world. Green Energy Park will produce some of the most cost competitive Green Hydrogen at the gigawatts scale, servicing the decarbonization needs of the hard to abate sectors, including transport and power across Europe and elsewhere around the world.
MT Group’s expertise extends to the development and construction of renewable energy, hydrogen and carbon capture facilities, positioning the company at the forefront of sustainable engineering solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240915027054/en/
Contacts
Migle Poskute Klimasauskiene
Migle Poskute Klimasauskiene
M.: +370 656 57230
E.: m.klimasauskiene@mtgroup.lt
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press release
- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and t
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press release
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Andersen Global udvider sin ekspertise med tilføjelsen af Valora20.12.2024 17:07:00 CET | Pressemeddelelse
Andersen Global fortsætter sin udvidelse af servicetilbud gennem en samarbejdsaftale med Valora, der er en uafhængig virksomhed med speciale i levering af skræddersyede løsninger til både private og institutionelle kunder globalt. Valora har kontorer i Miami og Raleigh og desuden global tilstedeværelse i Den Dominikanske Republik, Storbritannien og Caymanøerne. Valora blev grundlagt i 2011 af partneren Luis de Leon og tilbyder et stort udvalg af tjenester, blandt andet værdiansættelse, performance, regnskab og administration, global enhedsstyring, fondsvirksomhed og andre skræddersyede løsninger. "Et samarbejde med Andersen passer godt til både vores kunder og vores team," siger Luis. "Synergierne mellem for vores servicetilbud vil sætte os i stand til at levere omfattende og integrerede løsninger med stadigt stigende global rækkevidde." Global Chairman og CEO for Andersen Mark L. Vorsatz udtaler: "Valoras team og virksomhedskultur er, sammen med deres fokus på det praktiske, et godt m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom